ANO1 and cystic fibrosis: Because our data so far have uncoupled TMEM16A from a possible causal effect on mucus, this channel seems to remain a good potential drug target for CF through its activation (not inhibition) to compensate for the absence of CFTR-mediated Cl−/HCO3− secretion.